![]() |
Cellcept info
I ran across this info. I don't take Cellcept, and am not really sure what effect this news has on those who take it, but thought I would post it for those of us who take Cellcept.
Completed our global clinical trial evaluating the use of CellCept® for the treatment of myasthenia gravis (MG). Based on the results of this trial, Aspreva does not intend to continue any further development of CellCept for the treatment of MG. It is from: http://www.bctechnology.com/scripts/...s.cfm?id=24084 I hope this doesn't mean the drug will no longer be available! :eek: Hugs, |
Cellcept
Interesting article about cellcept. I have been on cellcept since 2000 and have had a good response to the drug. It appears in the article that the research study did not support the use of cellcept for MG. I am going to take the article to my neuro on the 21st and see what she thinks. I too hope it will continue to be available for MG use, but if it becomes "off label" for the drug indications, it is possible insurances won't cover it. It is a very expensive drug so that would be bad for us. Will have to do some research on this. Thanks for posting that article.
|
cellcept
:confused: I did a little more research. There have been at least 2 studies that did show impact on MG with cellcept and it is FDA approved for MG. I did read the research study findings from the link you posted, and the study was completed with patients not meeting the desired outcomes so it sounds like the company is not planning to do any further research to demonstrate cellcept as drug for MG. Don't know what it would mean, or why they did this study if the drug is already approved by FDA. I saw the company is in Canada - so maybe it isn't approved in Canada yet?? I am hopeful it won't mean much of anything, but I am going to discuss with my neuro.....
|
All times are GMT -5. The time now is 08:30 PM. |
Powered by vBulletin Copyright ©2000 - 2025, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise (Lite) -
vBulletin Mods & Addons Copyright © 2025 DragonByte Technologies Ltd.